Koninklijke Philips (NYSE:PHG) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Koninklijke Philips (NYSE:PHG) announced its quarterly earnings results on Wednesday. The technology company reported $0.54 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.55 by ($0.01), Zacks reports. The company had revenue of $5.38 billion during the quarter, compared to the consensus estimate of $5.10 billion. Koninklijke Philips had a positive return on equity of 10.94% and a negative net margin of 3.88%.

Koninklijke Philips Stock Down 0.1 %

Shares of PHG opened at $25.04 on Friday. Koninklijke Philips has a one year low of $19.55 and a one year high of $32.91. The stock’s fifty day moving average is $26.25 and its 200-day moving average is $28.16. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.16 and a quick ratio of 0.74.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on PHG shares. StockNews.com upgraded Koninklijke Philips from a “hold” rating to a “buy” rating in a research note on Thursday. Jefferies Financial Group upgraded shares of Koninklijke Philips from an “underperform” rating to a “hold” rating in a research report on Tuesday, October 29th. Finally, UBS Group upgraded shares of Koninklijke Philips from a “neutral” rating to a “buy” rating in a research report on Thursday. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy”.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.